All In Biotech

Drug Trial Radar · NCT07535970

A Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HS-10506 in Healthy Chinese Adult Participants

Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Apr 30, 2026

Primary completion

Jul 30, 2026

Study completion Jul 30, 2026

Sponsor

Sponsor type
Industry
First posted
Apr 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A single-center, open-label, fixed-sequence, self-controlled phase I clinical trial aimed at evaluating the effect of itraconazole capsules(CYP3A inhibitor) on the pharmacokinetics of HS-10506 tablets in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • HS-10506, ItraconazoleDrug

    HS-10506: Administered under fasting conditions in the morning. Itraconazole: Itraconazole capsules (0.2 g) are taken orally once daily for nine consecutive days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluation of PK parameters of HS-10506: CmaxTime frame: 120 hours after administration of HS-10506
  2. Evaluation of PK parameters of HS-10506: AUC0-tTime frame: 120 hours after administration of HS-10506
  3. Evaluation of PK parameters of HS-10506: AUC0-∞Time frame: 120 hours after administration of HS-10506

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.